MAPT and Alzheimer disease: Classic AD CSF biomarkers are characterized by low concentrations of amyloid-β (Aβ)1–42 and high concentrations of phosphorylated tau181p (p-tau) and total tau (t-tau) (Olsson et al., 2016; Jack et al., 2018).